US Stock MarketDetailed Quotes

AZN AstraZeneca

Watchlist

76.210
+0.560+0.74%

Close Feb 28 16:00 ET

76.200
-0.010-0.01%

Post 20:01 ET

236.27BMarket Cap33.87P/E (TTM)

AstraZeneca Stock Forum

Teddy123

Feb 28 07:12

$AstraZeneca (AZN.US)$
ENHERTU Shows 38% Reduced Death Risk in Breast Cancer - EU Approval Now One Step Closer

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Teddy123

Feb 26 06:14

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor

$AstraZeneca (AZN.US)$
Can This Breakthrough Breast Cancer Drug Transform AstraZeneca's Oncology Portfolio?

Ryand83

Feb 24 18:28

$LumiraDx (LMDXF.US)$ if we started bringing awareness to X FB and other social media platforms we could probably win this fight. I stayed in Lumiradx because I figured if $AstraZeneca (AZN.US)$ had scooped it up we would have been jipped. $ROCHE HOLDING AG (RHHBY.US)$ seemed like a better fit as they have a plethora of innovative solutions to revitalize companies. 350m seems like an $Abbott Laboratories (ABT.US)$ or $Johnson & Johnson (JNJ.US)$ move to me and I don't buy it. Not from Roche.

Teddy123

Feb 24 03:05

Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing

$Sophia Genetics (SOPH.US)$ $AstraZeneca (AZN.US)$
Global Healthcare Revolution: Elite Hospitals Rush to Implement This Game-Changing Cancer Test

Teddy123

Feb 14 13:14

IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-h

$AstraZeneca (AZN.US)$
Breakthrough in Bladder Cancer Treatment: AstraZeneca's IMFINZI Slashes Disease Progression Risk by 42%

Teddy123

Feb 12 04:39

New Interactive Storybook Aims to Educate Children with Rare Kidney Disease into a World of Adventure and Understanding

$AstraZeneca (AZN.US)$
Groundbreaking Digital Adventure Helps Kids Master Their Rare Kidney Disease Journey

Teddy123

Jan 30 23:37

TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse

$AstraZeneca (AZN.US)$ $Compugen (CGEN.US)$
Major Breakthrough: AstraZeneca's New Weapon Against Early-Stage Lung Cancer Enters Final Testing

Ryand83

Jan 26 11:47

$LumiraDx (LMDXF.US)$ @BadPaint revisiting your Bill Gates post about him not selling his shares. It was announced while Lumiradx was on expert market I believe. Now I will say this, all the institutions that sold could have sold prior to expert market and bought back in during expert through an offshore entity. Zwanziger Ventures LLC perhaps? Can you dig more into Senvest for us?
Off topic here a bit however I found this intriguing that Cobas was introduced in '94 however Roche only started divi...

10xStockPicks

Jan 23 07:47

Today 3 Analysts Place BUY Ratings On This $2 Stock $7,$9 & $16 Which Is An Acquisition Target by BIG Pharma

$Esperion Therapeutics (ESPR.US)$ Jan 23, 2025 Three analysts are bullish on Esperion Therapeutics with price targets on this $2 stock ranging from $7 to $16 a share.
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...